Study Name:
Randomized Phase III Comparing Everolimus Plus Placebo versus Everolimus Plus Bevacizumab for Advanced Renal Cell Carcinoma Progressing after Treatment with Tyrosine Kinase Inhibitors
|
|
Purpose:
This randomized phase III trial is studying giving everolimus together with bevacizumab to see how well it works compared to everolimus alone in treating patients with advanced kidney cancer that progressed after first-line therapy.
|
|
Study Type: Treatment
Protocol: UIC 2011-0372 CALGB 90802
|
|
For study details, click here.
Internal users only: click here for protocol details and forms. |
Study Name:
A Randomized, Double-Blind, Placebo-Controlled Phase III Study of Early versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men with Prostate Cancer Metastatic to the Bone.
|
|
Purpose:
This randomized phase III trial is studying how well zoledronate works in preventing bone-related events in patients who are receiving androgen deprivation therapy for prostate cancer and bone metastases.
|
|
Study Type: Treatment
Protocol: UIC 2004-0677 CALGB 90202
|
|
For study details, click here.
Internal users only: click here for protocol details and forms. |
Study Name:
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab versus Placebo Following Radiotherapy in Subjects with Castration Resistant Prostate Cancer that have Received Prior Treatment with Docetaxel.
|
|
Purpose:
The purpose of the study is to determine if advanced prostate cancer patient s that are treated with radiotherapy (RT) plus ipilimumab live longer that those treated with RT alone.
|
|
Study Type: Treatment
Protocol: UIC 2010-0792 CA 184-043-0203
|
|
For study details, click here.
Internal users only: click here for protocol details and forms
|
Study Name:
Identification of Class I HLA-restricted Prostatic Epitopes for Specific T Cell Immunotherapy of Human Prostate Cancer.
|
|
Purpose:
To determine whether class I HLA-restricted T cells with specificity for identified prostatic epitopes lyse tumor cells.
|
|
Protocol: UIC 1999-0599
|
|
Internal users only: click here for protocol details and forms
|
Back to Oncology Clinical Trials Homepage